Viatris WAKIX Approved in Japan for Sleep Disorders
Tokyo, Japan, September 16, 2026 Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Tokyo, Japan, September 16, 2026 Viatris Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved...
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
MUMBAI, INDIA & NAPLES, USA | March 25, 2026 Lupin Limited, a global pharmaceutical leader, has received tentative approval...
